重组腺病毒介导IL-12、IL-2联合基因治疗前列腺癌的实验研究  

An experimental study on adenovirus-mediated IL-12 and IL-2 gene therapy for prostate cancer

作　　者：董焱鑫[1] 钱松溪[2] 曹广文[1] 潘卫[1] 赵晋新[2] 孙颖浩[2] 戚中田[1] 

机构地区：[1]第二军医大学微生物教研室 [2]长海医院泌尿外科

出　　处：《中华泌尿外科杂志》2002年第7期440-442,共3页Chinese Journal of Urology

摘　　要：目的　探讨转移性前列腺癌的治疗方法 ,为前列腺癌免疫基因治疗提供实验依据。　方法　采用重组腺病毒介导IL 12、IL 2联合免疫基因疗法 ,对 6 6只C5 7BL/ 6小鼠前列腺癌模型进行致瘤性和抑瘤性观察。　结果　腺病毒AdmIL 12、AdhIL 2能有效表达目的基因。接种野生型 ,转AdLacZ及转AdmIL 12、AdhIL 2混合RM 1细胞的小鼠致瘤比例分别为 10 / 10、10 / 10及 2 / 10 ;成瘤时间分别为 (12 .3± 1.5 )d、(12 .8± 1.0 )d、(2 2 .5± 2 .1)d ;接种 30d后肿瘤结节直径分别为 (35 .0±2 .0 )mm、(34 .0± 2 .6 )mm、(10 .5± 3.5 )mm。与对照组相比 ,转AdmIL 12、AdhIL 2基因RM 1细胞小鼠致瘤率下降 ,成瘤时间延迟 (P <0 .0 1)、瘤结节小 (P <0 .0 1)。AdmIL 12、AdhIL 2瘤体注射还可抑制肿瘤生长 (P <0 .0 1) ,减少肺转移灶数目 (P <0 .0 1)。　结论　IL 12、IL 2联合基因治疗可诱发前列腺癌小鼠的肿瘤特异性免疫反应。Objective To study the gene therapy of metastatic prostate cancer. Methods we investigated the ability of adenoviral vectors expressing cytokines IL-12 and IL-2 to induce regression of tumor in C57BL/6 mice models(n=66) of prostate cancer. Results Adenoviral vectors can express cytokines IL-12 and IL-2 proteins effectively. Only 20%(2/10) of mice inoculated with RM-1 cells engineered AdmIL-12 and AdhIL-2 developed smaller and delayed tumors ( P <0.01). Intratumoral injection of AdmIL-12 and AdhIL-2 could not only regress the established tumors, but also reduce the number of distal lung metastases. Conclusions It was implied that Adenovirus-mediated delivery of IL-12 and IL-2 locally by intratumoral injection is highly effective in inducing specific antitumor immune responses. Considering the anatomic site of prostate, it may be convenient for clinical immunogenetherapy for patients with prostate cancer.

关 键 词：重组腺病毒介导 IL-12 IL-2 联合治疗 基因治疗 前列腺癌 实验研究 

分 类 号：R737.25[医药卫生—肿瘤]